Table 3.
Determinants of non-persistence (>90-day gap) with anti-osteoporosis drugs after fracture
| Cr. HR (95 % CI) | Adj. HR (95 % CI) | |
|---|---|---|
| Gender | ||
| Male | Reference | Reference |
| Female | 0.91 (0.71–1.18) | 0.97 (0.74–1.26) |
| Age categories | ||
| 50–59 years | Reference | Reference |
| 60–69 years | 1.05 (0.75–1.47) | 1.06 (0.76–1.50) |
| 70–79 years | 1.15 (0.82–1.60) | 1.13 (0.80–1.58) |
| ≥80 years | 1.70 (1.20–2.42) | 1.65 (1.15–2.38) |
| Type of index fracture | ||
| Forearm | Reference | Reference |
| Humerus | 0.92 (0.65–1.31) | 0.87 (0.61–1.24) |
| Clinical vertebral | 1.22 (0.95–1.57) | 1.13 (0.87–1.47) |
| Hip | 1.24 (0.94–1.63) | 1.08 (0.81–1.44) |
| Dosage regime | ||
| Once daily | 1.21 (0.84–1.74) | 1.06 (0.73–1.54) |
| Once weekly | Reference | Reference |
| Once monthly | 0.58 (0.24–1.40) | 0.58 (0.24–1.41) |
| Drug usea | ||
| Systemic glucocorticoids | 1.21 (0.84–1.73) | 1.18 (0.82–1.70) |
| Antidepressants | 1.12 (0.81–1.55) | 1.11 (0.80–1.54) |
| Opioids (tramadol or stronger) | 1.00 (0.65–1.53) | 0.83 (0.53–1.29) |
| Non-steroidal anti-inflammatory drugs | 1.01 (0.79–1.31) | 0.98 (0.76–1.27) |
| Calcium supplements and/or vitamin D | 0.96 (0.77–1.19) | 0.94 (0.76–1.17) |
| Disease-modifying anti-rheumatic drugs | 1.01 (0.48–2.14) | 1.10 (0.52–2.34) |
| Disease occurrenceb | ||
| Dementia/Alzheimer’s disease | 1.71 (0.94–3.11) | 1.46 (0.79–2.70) |
| Subsequent fractures | 1.70 (0.91–3.21) | 1.64 (0.86–3.10) |
| Upper gastrointestinal disorders | 1.54 (0.79–3.00) | 1.40 (0.71–2.74) |
| Alcoholism | 1.55 (0.80–3.01) | 1.50 (0.76–2.96) |
Cr crude, Adj adjusted, HR hazard ratio, 95 % CI 95 % confidence interval
aReference group is no use within 6 months prior within that drug category
bReference group is no occurrence within 6 months prior (ever prior for dementia/Alzheimer’s disease or alcoholism) within that disease category